The WHO/HRP Prevention of Unsafe Abortion unit is developing a Target Product Profile (TPP) for a point-of-care (POC) or near-POC technology to detect substandard or falsified mifepristone and misoprostol—two essential medicines used in medical abortion.
A WHO TPP serves as a key reference for product developers, regulatory authorities, procurement agencies, and funders. It helps align research and development efforts with public health priorities and supports the rapid development of products addressing essential health needs. We developed the draft TPP following WHO standard procedure which includes expert interviews, an international online survey, and public consultation to ensure stakeholder perspectives are incorporated.
We are now posting the draft TPP for public consultation and invite you to share your feedback through the form that can be uploaded in the survey here. You are welcome to provide high-level feedback on the TPP, or detailed feedback on the variables. All inputs are valuable and can be included in the feedback form.
You will be asked to provide your name, contact details, and basic professional information when submitting the feedback form. However, we will treat your feedback anonymously and your name will never appear publicly. If you encounter any problem, please reach out to srhpua@who.int.
Thank you for input.
There are 3 questions in this survey.
